

S3 Table. Antitumor activity of immune checkpoint inhibitors for MMRd/MSI-H tumor (n=38)

Tumor type	No.	CR, n (%)	PR, n (%)	ORR (%)
Endometrium	15	2 (13.3)	3 (20.0)	33.3
Cervix	8	0	1 (12.5)	12.5
Ovary/Peritoneum/Fallopian tube	7	0	1 (14.3)	14.3
Uterine corpus	6	0	2 (33.3)	33.3
Gestational trophoblast	2	1 (50.0)	1 (50.0)	100.0

CR, complete response; MMRd, mismatch repair deficiency; MSI-H, microsatellite high; ORR, objective response rate; PR, partial response.